Proud to share that VRG Therapeutics is entering a co-development partnership and option agreement with AOP Health to advance a new immunology program.
This collaboration brings together our AI-driven miniprotein discovery platform with AOP Health’s clinical development expertise, with the shared goal of accelerating a novel immune cell activity regulator toward first-in-human studies for autoimmune and inflammatory diseases.
Excited for what’s ahead!
AOP Health and VRG Therapeutics have entered a co-development partnership for a new immunology program!
By joining the forces of VRG’s AI-driven miniprotein platform and AOP Health’s clinical development expertise, our companies aim to accelerate progress toward first-in-human studies of a novel key immune cell activity regulator, in autoimmune and inflammatory diseases.
Read more here
